Enfermedad inflamatoria intestinal
La incidencia de la enfermedad inflamatoria intestinal tienen que ver mucho con la alimentacion como podemos observar, aunque hay un componente genetico elevado:
Estamos terminando con las enfermedades contagiosas y viricas, pero se incrementan las autoinmunes:
San Diego-based Receptos is on a roll. After the markets closed on Monday, the biotech ($RCPT) spread the word that its mid-stage trial for lead drug RCP1063 hit its primary endpoint for spurring remissions and clinical responses among patients suffering from ulcerative colitis in the trial. And the results quickly spurred a 37% spike in its share price, which follows a similar surge when the same drug hit its marks in a mid-stage trial for multiple sclerosis back in the summer.
The drug is a sphingosine 1-phosphate 1 receptor–S1P1R–small molecule modulator; essentially a pill designed to prevent circulating lymphocytes from provoking autoimmune diseases. Analysts were particularly cheered by the news because it helps provide solid data that Receptos–which pulled off a stellar IPO in 2013 largely on the promise of this drug–is on the right track for MS, ulcerative colitis as well as Crohn’s and other conditions.